Pleural Effusion Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Pleural effusion Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Pleural effusion pipeline landscape. It covers the Pleural Effusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pleural Effusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Pleural Effusion Pipeline Report
- DelveInsight’s Pleural Effusion pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pleural Effusion treatment.
- The leading companies working in the Pleural Effusion Market include Lung Therapeutics, Wuhan YZY Biopharma Co., Ltd., RS Oncology, Wuhan Binhui Biotechnology Co., Ltd, Sichuan Clover Biopharmaceuticals Inc., LIPAC Oncology, and others.
- Promising Pleural Effusion Pipeline Therapies in the various stages of development include Abnoba Viscum F 20mg, LTI-01, JMKX000197, SCB-313, Endostar, Cisplatin, and others.
- September 2023: RS Oncology LLC announced a study of Phase 1 & 2 clinical trials for RSO-021. This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.
- October 2023: M.D. Anderson Cancer Center announced a study of Phase 2 clinical trials for Intrapleural catheter (IPC) drained and IPC Placement. The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.
- October 2023: Memorial Healthcare System announced a study of Phase 4 clinical trials for Cathflo Activase and Talc Slurry Pleurodesis. Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion. This protocol describes a prospective, randomized, double-blind controlled trial comparing TSP alone to the combination of TSP with cathflo activase for achieving optimal results with pleurodesis for recurrent pleural effusion. Patients who sign informed consent will be randomly assigned to receive either TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml NS) or TSP with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter. Follow-up lasts for three months.
Request a sample and discover the recent advances in Pleural Effusion Treatment Drugs @ Pleural Effusion Pipeline Report
In the Pleural Effusion pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pleural effusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pleural Effusion Overview
Pleural effusion is the accumulation of fluid in between the parietal and visceral pleura, called the pleural cavity. It can occur by itself or can be the result of surrounding parenchymal disease like infection, malignancy, or inflammatory conditions. Pleural effusion is one of the major causes of pulmonary mortality and morbidity.
Find out more about Pleural Effusion Therapeutics Assessment @ Pleural Effusion Preclinical and Discovery Stage Products
Pleural Effusion Emerging Drugs Profile
- LTI-01: Lung Therapeutics
- M701: Wuhan YZY Biopharma
Pleural Effusion Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the Pleural effusion therapies. The Pleural effusion companies which have their Pleural effusion drug candidates in the most advanced stage, i.e. phase II include, Lung Therapeutics.
DelveInsight’s Pleural Effusion pipeline report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Pleural effusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Pleural Effusion Pipeline Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Learn more about the emerging Pleural Effusion Pipeline Therapies @ Pleural Effusion Clinical Trials Assessment
Scope of the Pleural Effusion Pipeline Report
- Coverage- Global
- Pleural Effusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Pleural Effusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Pleural Effusion Companies- Lung Therapeutics, Wuhan YZY Biopharma Co., Ltd., RS Oncology, Wuhan Binhui Biotechnology Co., Ltd, Sichuan Clover Biopharmaceuticals Inc., LIPAC Oncology, and others.
- Pleural Effusion Pipeline Therapies- Abnoba Viscum F 20mg, LTI-01, JMKX000197, SCB-313, Endostar, Cisplatin, and others.
Dive deep into rich insights for new drugs for Pleural Effusion Treatment, Visit @ Pleural Effusion Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Pleural effusion: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pleural effusion – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- LTI-01: Lung Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- M701: Wuhan YZY Biopharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Pleural effusion Key Companies
- Pleural effusion Key Products
- Pleural effusion- Unmet Needs
- Pleural effusion- Market Drivers and Barriers
- Pleural effusion- Future Perspectives and Conclusion
- Pleural effusion Analyst Views
- Pleural effusion Key Companies
- Appendix
For further information on the Pleural Effusion Pipeline therapeutics, reach out to Pleural Effusion Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pleural-effusion-market
